Kraus JE, Horrigan JP, Carpenter DJ, et al. Clinical features of patients with treatment-emergent suicidal behavior following initiation of paroxetine therapy. J Affect Disord. 2010;120(1-3):40-47.
Abstract
Background
Understanding suicidal behavior is an important component of assessing suicidality in psychiatric patients. GlaxoSmithKline (GSK) conducted a meta-analysis of randomized, placebo-controlled trials to compare suicidality in adult patients treated with paroxetine vs. placebo. The goal was to identify emergent clinical characteristics of patients with definitive suicidal behavior (DSB: preparatory act, suicide attempt, completed suicide).
Continue reading "Clinical features of patients with treatment-emergent suicidal behavior following initiation of paroxetine therapy." »
Tang TZ, DeRubeis RJ, Hollon SD, et al. Personality Change During Depression Treatment: A Placebo-Controlled Trial. Arch Gen Psychiatry. 2009;66(12):1322-1330.
Context High neuroticism is a personality risk factor that reflects much of the genetic vulnerability to major depressive disorder (MDD), and low extraversion may increase risk as well. Both have been linked to the serotonin system.
Continue reading "Personality Change During Depression Treatment" »
TRIAP – (TRICARE Assistance Program) & TAMP (Transition Assistance Management Program)
The web-based TRICARE Assistance Program (TRIAP) Demonstration began on August 1, 2009 in the U.S. and will continue until April 1, 2010. The purpose of the demonstration is to test the use of web-based technologies to:
- Deliver information and counseling services to our beneficiaries
- Determine if web-based technologies increases efficiency of identifying beneficiaries who need behavioral health care
- Identify behavioral health needs of our beneficiaries earlier
- Refer and get beneficiaries access to the appropriate level of behavioral health care more effectively.
Continue reading "TRIAP and TAMP: Web based behavioral health care" »